Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: Comparison of beta-lactams

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 11, 2010, Pages

  Paul, Mical ^a   Yahav, Dafna ^b   Bivas, Assaf ^b   Fraser, Abigail ^c   Leibovici, Leonard ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFPIRAMIDE; CEFPIROME; CEFTAZIDIME; CEFTOBIPROLE; GLYCOPEPTIDE; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; CEPHALOSPORIN DERIVATIVE; DRUG DERIVATIVE; PENICILLANIC ACID; THIENAMYCIN DERIVATIVE;

ADVERSE OUTCOME; ALL CAUSE MORTALITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL SUPERINFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; MYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK ASSESSMENT; SEIZURE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; VOMITING; FEVER; META ANALYSIS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORINS; FEVER; HUMANS; IMIPENEM; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIENAMYCINS;

EID: 79952066185     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005197.pub3     Document Type: Review

References (163)

1. Anaissie EJ, Fainstein V, Bodey GP, Rolston K, Elting L, Kantarjian H, et al.Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. American Journal of Medicine 1988;84(3 Pt 2):581-9.
2. Aoun M, Boogaerts MA, Bosly AJ, Schots H. A multicenter, randomized, prospective, comparative study of cefepime plus vancomycin versus ceftazidime plus vancomycin as empiric therapy in the treatment of febrile episodes in granulocytopenic patients with hematological malignancies. Joint clinical/statistical review of NDA 50, 679/SE1-002: study AI411-198 1997:122-32.
3. Breen J, Ramphal R, Cometta A, Conetta B, Nicaise C. Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients. In: Klastersky J editor(s). Febrile neutropenia. Berlin: Springer-Verlag, 1997:63-74.
4. Aparicio J, Gomez-Aldaravi L, Pastor M, Munarriz B, Gomez J, Maestu, et al.Randomized comparison of Ceftazidime and Imipenem in oncologic patients with neutropenic fever [Comparacion aleatorizada de Ceftazidima e Imipenem en pacientes oncologicos con fiebre neutropenica]. Oncologia. IV Congreso Nacional de la SEOM. 1993; Vol. 16, issue 6 -congreso:248.
5. Aparicio J, Montalar J, Gomez-Aldaravi L, Pastor M, Gomez-Codina J, Herranz C. Ceftazidime versus imipenem as initial monotherapy in oncologic patients with fever and neutropenia: preliminary results of a randomized trial. Neoplasia 1993;10(4):122-25.
6. Aparicio J, Oltra A, Llorca C, Montalar J, Herranz C, Gomez-Codina J, et al.Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. European Journal of Cancer 1996;32A(10):1739-43.
7. Bickers J, Gumbart C, Cavalier J, Vial R, Ostroske DR, Veith R. A prospective randomized trial of cefoperazone plus sulbactam versus imipenem-cilastatin in febrile neutropenic patients. Clinical Research. 1990; Vol. 38:991A.
8. Bickers J, Gumbart C, Vial R. A prospective randomized trial of cefoperazone plus sulbactam versus imipenem-cilastatin in febrile, neutropenic patients. Program and abstracts of the 18th international congress of chemotherapy. Stockholm, 1993; Vol. abs 569:217.
9. Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, et al.Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). Journal of Antimicrobial Chemotherapy 1998;42(4):511-18.
10. Biron P, Fuhrmann C, Kheder K, Viens P, Lefebvre D, Beal J, et al.Cefepime (CEP) vs Imipenem-cilastatin (IMP) as empiric monotherapy in 400 febrile patients with short duration neutropenia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Ontario, Canada, 1997.
11. Fuhrmann C, Beal J, Escande MC, Lebrun-Jezekova D, Lefebre D, Lesimple T, et al.Cepemine (CEP) vs Imipenem-cilastatin (IMP) as empiric monotherapy in 400 febrile patients with short duration neutropenia. Supportive Care in Cancer 1998;6 Suppi(Abs No 74):323.
12. Bodey GP, Fainstein V, Elting LS, Anaissie E, Rolston K, Khardori N, et al.Beta-lactam regimens for the febrile neutropenic patient. Cancer 1990;65(1):9-16.
13. Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. European Journal of Clinical Microbiology and Infectious Diseases 1996;15(8):625-34.
14. Bohme A, Shah PM, Stille W, Hoelzer D. Cefepime (CEFP) versus piperacillin/tazobactam (PIP/TAZ) as initial antimicrobial therapy in febrile granulocytopenic patients. Annals of Hematology 1996;73(Suppl 2):A44.
15. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. European Journal of Medical Research 1998;3(7):324-30.
16. Boogaerts MA, Demuynck H, Mestdagh N, Verbist L, Goldstone AH, Kelsey HC, et al.Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 1995;36(1):185-200.
17. De-Pauw B, Donnely P, Boogaerts MA, Mesidagh N, Machin SJ, Goldstone AH, et al.Meropenem or ceftazidime empiric therapy for febrile neutropenic adults. 32nd Intersciense Confernce on Antimicrobial Agents and Chemotherapy. Anaheim, California, USA, 1992; Vol. Abs No 1693.
18. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal?. Scandinavian journal of infectious diseases. Supplementum 1995;96:34-37.
19. Bow EJ, Noskin GA, Schwarer AP, Laverdiere M, Vesole DH. Efficacy of Piperacillin/Tazobactam as Initial Empiric Therapy of Febrile Neutropenia in Patients with Hematologic Malignancy. 45th Annual Meeting of the Americal Society of Hematology. San Diego, 2003:Abstract no. 1000.
20. Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, et al.A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clinical Infectious Diseases 2006;43(4):447-59.
21. Bow EJ, Schwarer AP, Laverdiere M, Segal BH, Anaissie E. Efficacy of Piperacillin/Tazobactam as Initial Empiric Therapy of Febrile Neutropenia in Patients with Hematologic Malignancy. 43th Interscience conferemce on antimicrobials agents and chemotherapy. Chicago: American Society for Microbiology, 2003:Abstract no. L-114.
22. Noskin GA, Vesole D, Szer J, Sanche S, McCarthy AE. Annual Meeting of the Infectious Diseases Society of America. San Diego, 2003:Abstract no. 373.
23. Breen J, Ramphal R, Cometta A, Conetta B, Nicaise C. Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients. In: Klastersky J editor(s). Febrile neutropenia. Berlin: Springer-Verlag, 1997:63-74.
24. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. The Annals of Pharmacotherapy 2000;34(9):989-95.
25. Hathorn J, Chandrasakar P, Baird I, Arnow P, Waskin A. Double-blind Comparison of Cefepime vs Ceftazidime to Treat Febrile Neutropenia. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996.
26. Hathorn JW, Chandrasekar PH, Baird I, Arnow P, Velasquez W, Heimenz J. A double-blind randomized trial of cefepime versus ceftazidime fort the empirical treatment of febrile episodes in neutropenic cancer patients. Joint clinical/statistical review of NDA 50, 679/SE1-002: study AI411-204 1997:26-50.
27. Cherif H, Bjorkholm M, Engervall P, Johansson P, Ljungman P, Hast R, et al.A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scandinavian Journal of Infectious Diseases 2004;36(8):593-600.
28. Cherif H, Engervall P, Bjorkholm M, Kalin M. Comparison of cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies: a prospective, randomised, multicentre study [abstract]. 8th Congress of the European Hematology Association 2003. Lyon, France, 2003; Vol. abs no. 854.
29. Chuang YY, Hung IJ, Yang CP, Jaing TH, Lin TY, Huang YC. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatric Infectious Diseases Journal 2002;21(3):203-209.
30. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatric Hematology and Oncology 2006;23(3):177-186.
31. Cornely OA, Reichert D, Buchheidt D, Maschmeyer G, Wilhelm M, Schiel X, et al.Three-Armed Multicenter Randomized Study on the Empiric Treatment of neutropenic Fever in a High Risk Patient Population (PEG Study III). In ICAAC. Chicago; 2001. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001:P446.
32. Maschmeyer G. Cefepime in the initial treatment of high-risk febrile neutropenic patients [Cefepim in der empirischen Initial therapie bei febrilen neutropenischen Patienten mit mignen erkankungen]. Chemotherapie Journal 2004;13:174-80.
33. De Pauw B. Initial empiric monotherapy with metropenem or ceftazidime in high risk cancer patients with febrile neutropenia. Supportive Care in Cancer 2000;8 Suppl(Abstr. 49):157.
34. Feld R, De Pauw B, Berman S, Keating A, Ho W. Meropenem (MEM) Versus Ceftazidime (CAZ) for Initial Empiric Therapy in Cancer Patients with Febrile Neutropenia: Results of a Double-Blind, Randomized, Multicenter Trial. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, 1999; Vol. Abs No. 1091:722.
35. Feld R, De Pauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. Journal of Clinical Oncology 2000;18(21):3690-98.
36. Figuera A, Rivero N, Pajuelo F, Font P, Leyra F, De-la-Camara R, Arranz R, et al.Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996). Medicina Clinica 2001;116(16):610-11.
37. Fleischhack G, Hartmann C, Simon A, Wulff B, Havers W, Marklein G, et al.Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. Journal of Antimicrobial Chemotherapy 2001;47(6):841-53.
38. Hartmann C, Fleischhack G, Wulff B, Havers W, Hasan C, Bode U. A randomized comparison of ceftazidime versus meropenem in febrile neutropenia in pediatric cancer patients. Supportive Care in Cancer 2000;8 suppl(Abs No 48):156.
39. Fallon J, Rubin M, Hathorn J, Callender D, Albano E, Walsh TJ, et al.Is a carbapenem as effective as a III generation cephalosporin when used as monotherapy in the empiric treatment of the febrile neutropenic patient?. 27th Interscience conference on Antimicrobial Agents Chemotherapy. Washington DC, 1987; Vol. Abs No. 1254.
40. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al.Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. Journal of Clinical Oncology 1995;13(1):165-76.
41. Rubin M, Pizzo PA. Monotherapy for empirical management of febrile neutropenic patients. National Cancer Institute Monographies 1990;9:111-6.
42. Ghalaut PS, Chaudhry U, Ghalaut VS, Aggarwal S, Sood V, Dixit G. Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies. Indian Journal of Hematology and Blood Transfusion 2007;23(3-4):104-6.
43. Breen J, Ramphal R, Cometta A, Conetta B, Nicaise C. Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients. In: Klastersky J editor(s). Febrile neutropenia. Berlin: Springer-Verlag, 1997:63-74.
44. Glauser M, Dekker AW, Van Marwijkkooy M, Palmblad J, Wood M, Harper P. A multicenter comperative study of cefepime vs. ceftazidime as empiric therapy in the treatment of febrile episodes in neutropenic patients. Joint clinical/statistical review of NDA 50, 679/SE1-002: study AI411-189 1997:51-74.
45. Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T, et al.Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplantation 2006;37(4):373-79.
46. Kebudi R, Gorgun O, Ayan I, Gurler N, Akici F, Toreci K. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Medical and Pediatric Oncology 2001;36(4):434-341.
47. Kutluk T, Kurne O, Akyuz C, Ceyhan M, Kanra G, Buyukpamukcu M, et al.Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatric Blood & Cancer 2004;42(3):284-86.
48. Kwon KT, Cheong HS, Rhee JY, Wi YM, Ryu SY, Heo ST, et al.Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Japanese Journal of Clinical Oncology 2008;38(1):49-55.
49. Liang R, Yung R, Chiu E, Chau PY, Chan TK, Lam WK, et al.Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrobial Agents and Chemotherapy 1990;34(7):1336-41.
50. Lindblad R, Rodjer S, Adriansson M, Andreasson B, Backstrom B, Johansson P, et al.Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime. Scandinavian Journal of Infectious Diseases 1998;30(3):237-43.
51. Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatric Infectious Diseases Journal 2001;20(3):362-69.
52. Oguz A, Karadeniz C, Citak EC, Cil V, Eldes N. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatric Hematoly Oncology 2006;23(3):245-53.
53. Oppenheim BA, Morgenstern GR, Chang J. Safety and efficacy of piperacillin/tazobactam versus meropenem in the treatment of febrile neutropenia. Proceeding of the 7th Conference of the Federation of Infection Societies. 2000:page 67, 52.
54. Oztoprak N, Piskin N, Aydemir H, Celebi G, Akduman D, Keskin AS, et al.Piperacillin-tazobactam Versus Carbapenem Therapy With andWithout Amikacin as Empirical Treatment of Febrile Neutropeniain Cancer Patients: Results of an Open Randomized Trialat a University Hospital. Japanese Journal of Clinical Oncology 2010;40(8):761-67.
55. Raad II, Whimbey EE, Rolston KV, Abi-Said D, Hachem RY, Pandya RG, et al.A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996;77(7):1386-94.
56. Raad II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, et al.Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;98(5):1039-47.
57. Breen J, Ramphal R, Cometta A, Conetta B, Nicaise C. Cefepime versus Ceftazidime as empiric therapy of febrile episodes in neutropenic patients. In: Klastersky J editor(s). Febrile Neutropenia. Berlin: Springer-Verlag, 1997:63-74.
58. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. The American Journal of Medicine 1996;100(suppl 6A):83S-89S.
59. Ramphal R, Haddow A, McCracken GH. A comparative study of cefepime vs. ceftazidime in the treatment of adult cancer patients with fever and neutropenia. Joint clinical/statistical review of NDA 50, 679/SE1-002: study AI411-131 1997:75-89.
60. Reich G, Cornely OA, Sandherr M, Kubin T, Krause S, Einsele H, et al.Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. British Journal of Haematology 2005;130(2):265-70.
61. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al.A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine 1992;152(2):283-91.
62. Shah PM, Heller A, Fuhr HG, Walther F, Halir S, Schaumann R, et al.Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996;24(6):480-84.
63. Shichmanter R, Miller E, Shtalrid M, Landau Z. Empiric antibiotic treatment of adults with neutropenic fever in a general internal medicine ward. In 14th European Congress of Clinical Microbiology and Infectious Diseases. 14th European Congress of Clinical Microbiology and Infectious Diseases. 2004; Vol. European Society of Clinical Microbiology and Infectious Diseases.
64. Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. American Journal of Hematology 2002;71(4):248-55.
65. Uygun V, Karasu GT, Ogunc D, Yesilipek A, Hazar V. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. Pediatric Blood Cancer 2009;53(4):610-4.
66. Vandercam B, Gerain J, Humblet Y, Ferrant A, Wauters G, Moreau M, et al.Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Annals of Hematology 2000;79(3):152-57.
67. Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatrics International EPUB;EPUB:EPUB.
68. Wang FD, Liu CY, Hsu HC, Gau JP, Chau WK, Haung ML, et al.A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999;45(5):370-79.
69. Winston DJ, Bartoni K, Bruckner DA, Schiller GJ, Territo MC. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clinical Infectious Diseses 1998;26(3):576-83.
70. Bauduer F, Cousin T, Boulat O, Attal M, Molina L, Rossi JF. A Randomized Prospective Multicenter Trial of Cefpirome vs. Piperacillin-Tazobactam in Febrile Neutropenia. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, 1999; Vol. Abs No 1089:720.
71. Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, Molina L, Fegueux N, et al.A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leukemia and Lymphoma 2001;42(3):379-86.
72. Bodey GP. Evolution of antibiotic therapy for infection in neutropenic patients: studies at MD Anderson Hospital. Reviews of Infectious Diseases 1989;11 Suppl 7:S1582-S1590.
73. Borja J, Herreras A. Comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clinical Infectious Diseases 1999; Vol. 28, issue 2:406-07.
74. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al.Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrobial Agents and Chemotherapy 1995;39(2):445-52.
75. Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. Journal of Chemotherapy 1996;8(5):375-81.
76. Cordonnier C, Delmer A, LeBlond V. A multi-investigator comparative study of cefepime and ceftazidime, in combination with amikacin for the treatment of patients with fever and neutropenia. NDA AI411-186.
77. Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, et al.Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clinical Infectious Diseases 1997;24(1):41-51.
78. Cornely OA, Bethe U, Seifert H, Breuer K, Schütt-Gerowitt H, Salzberger B, et al.A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs. cefepime and gentamicin. Annals of Hematology 2002;81(1):37-43.
79. Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 1996;37(5):975-86.
80. Erman M, Akova M, Akan H, Korten V, Ferhanoglu B, Koksal I, et al.Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Scandinavian Journal of Infectious Diseases 2001;33(11):827-31. [PUBMED: 11760163]
81. Fanci R, Leoni F, Ciolli S, Caporale R, Longo G, Rossi FP. Randomized assessment of tienam vs. ceftazidime for the empirical therapy of suspected bacterial infections in neutropenic patients: preliminary results. Haematologica 1992;77 Suppl 1:157-59.
82. Gomez L, Estrada C, Gomez I, Marquez M, Dalmau D, Estany C, et al.Cefepime Plus Amikacin versus Piperacillin-Tazobactam Plus Amikacin in the Treatment of Patients with Fever and Granulocytopenia. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA, 2001:Abstract L-771, p. 445.
83. Hoepelman AI, Kieft H, Aoun M, Kosmidis J, Strand T, Verhoef J, et al.International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. Journal of Antimicrobial Chemotherapy 1993;32 Suppl B:175-86.
84. Kieft H, Hoepelman AI, Rozenberg-Arska M, Branger JM, Voskuil JH, Geers AB, et al.Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrobial Agents and Chemotherapy 1994;38(3):415-21.
85. Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP. Safety profile of piperacillin/tazobactam in phase I and III clinical studies. Journal of Antimicrobial Chemotherapy 1993;31 Suppl A:113-24.
86. Longree L, De Bock R, Meyer S, et al.A multicenter comparative study of cefepime plus amikacin vs. piperacillin-tazobactam plus amikacin in the empiric treatment of febrile episodes in neurtopenic cancer patients. CAPTA study group, Belgium. 5th International Meeting on Febrile Neutropenia, Brussels. December 12-14, 2001.
87. Malik I. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia. Journal of the Pakistan Medical Association 2002;52(1):15-18.
88. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagnostic microbiology and infectious disease 1998;31(2):355-368.
89. Moroni C, Viscoli C, Boni L, Garaventa A, Dini G, Haupt R, Bruzzi P, Massimo L, Terragna A. A randomized study of the empirical antibiotic therapy of the infections in neutropenic patients, affected by neoplastic diseases in paediatric age and under a fever attack. Giornale di malattie infettive e parassitarie 1987;39(11):1194-2008.
90. Papachristodoulou A, Vaslamatzis M, Xynogalos S, Papacharalambous A, Alexopoulos CG. Ceftazidime (CFZ) monotherapy as empirical initial treatment of febrile neutropenia cancer patients (Pts). Annals of Oncology 1996;7(suppl 5):140.
91. Rolston KV, Jones PG, Fainstein V, Khardori NM, Anaissie EJ, Steelhammer L, et al.Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins. European Journal of Clinical Microbiology and Infectious Diseases 1991;10(3):139-45.
92. Sanz MA, Lopez J, Lahuerta JJ, Rovira M, Batlle M, Perez C, et al.Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2002;50(1):79-88.
93. Sanz MA, Villal L, Lahuerta JJ, Rovira M, Ribera JM, Perez C, et al.Cefepime Plus Amikacin Versus Piperacillin/Tazobactam Plus Amikacin for Initial Antibiotic Therapy in Hematological Patients with Febrile Neutropenia: Results of an Open, Randomized, Multicenter Trial. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000:474.
94. Smyth ETM, Barr JG, Hogg GM, Oppenheim BA. A pharmacoeconomic evaluation of piperacillin/tazobactam versus meropenem in the treatment of adult febrile neutropenia. Journal of Medical Economics 2002;5:135-45.
95. Sumitani Y, Kobayashi Y. Ceftazidime vs cefepime: comparison of two drugs as empirical therapeutic drugs for febrile neutropenia by Monte Carlo simulation method. ECCMID. 2007:Abstract 1722_873.
96. Tanindi S, Alpay F, Koseoglu V, Kurekci E, Ozcan O. Comparison of ceftazidime versus sulbactam/cefoperazone monotherapy as empiric therapy for febrile episodes in granulocytopenic children with cancer. Bulletin of Gulhane Military Medical Academy 1994;36(1):1-6.
97. Varthalitis I, Papadopoulou M, Vlachopoulos V, Pectasides D, Minitriadis M, Athanassiou AE. Cefepime (C) monotherapy in febrile patients (PTS) with chemotherapy induced neutropenia (Preliminary results). Annals of Oncology 1996;7(suppl 5):140.
98. Zarostsky V, Jaresko GS, Holtom PD. Piperacillin/tazobactam use in febrile neutropenic patients: a meta-analysis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, 2001:446.
99. Ma SY, Au WY, Lie AKW, Tse E, Leung AYH, Kwong YL. A prospective randomized trial of meropenem versus imipenem/cilastatin as monotherapy for neutropenic fever during early phase post stem cell transplantation. Blood 2003;102(11):439b (abstract 5484).
100. Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. International Journal of Infectious Diseases 2007;11(6):513-17.
101. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966;64(2):328-40.
102. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al.Fungal infections in cancer patients: an international autopsy survey. European Journal of Clinical Microbiology and Infectious Diseases 1992;11(2):99-109.
103. Burgess DS, Hall RG, 2nd. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagnostic Microbiology and Infectious Diseases 2004;49(1):41-6.
104. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infectious Control 2008;36(5):309-32.
105. Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al.Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiology and Infection 2009;EPUB:1-8.
106. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al.Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Annals of Internal Medicine 1991;115(8):585-90.
107. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
108. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2010;54(3):1111-6. [PUBMED: 20038614]
109. de Pauw BE, Donnelly JP. Infections in the immunocompromised Host: General Principles. In:. In: Mandell GL, Bennet JE, Dolin R editor(s). Mandell, Douglas and Bennet's Priciples and Practice of Infectious Diseases. Fifth edition. Philadelphia: Churchil Livingstone, 2000.
110. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Mu?oz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases 2008;46(12):1813-1821.
111. De -bock R, Cometta A, Kern WV, Aoun M, Caballero D, Engelhard D, et al.Incidence of Single Agent Gram-negative Bacteremias (SAGNB)in Neutropenic Cancer Patients (NCP) in EORTC-IATG Trials of Empirical Therapy for Febrile Neutropenia. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001:p. 445, abstract n° L-773.
112. Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 1996;37(5):975-86.
113. International Immunocompromised Host Society, European Conference on Infections in Leukaemic patients. Guidelines for the Management of Bacterial, Fungal and Viral Infections. http://www.ichs.org/ecilslides.htm.
114. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. Journal of Clinical Oncology 1998;16(3):1179-87.
115. US Food, Drug Administration. Information for Healthcare Professionals: Cefepime. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm167254.htm.
116. Kim PW, Wu YT, Cooper C, Rochester G, Valappil T, Wang Y, et al.Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clinical Infectious Diseases 2010;51(4):381-9.
117. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV, et al.Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinicsl Infectious Diseases 2002;35(12):1463-8.
118. Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12, 295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagnostic Microbiology and Infectious Diseases 2003;47(2):435-40.
119. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1996;40(5):1289-93.
120. Furno P, Dionisi MS, Bucaneve G, Menichetti F, Del Favero A. Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis. Supportive Care in Cancer 2000;8(4):293-301.
121. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clinical Microbiology and Infection 2002;8(12):823-5.
122. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch?nemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-26.
123. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
124. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002;34(6):730-51.
125. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-55.
126. Jacoby GA, Munoz-Price LS. The new beta-lactamases. New England Journal of Medicine 2005;352(4):380-91.
127. Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. Journal of Infectious Diseases 1990;162(4):981-3.
128. Kanafani ZA, Dakdouki GK, El-Chammas KI, Eid S, Araj GF, Kanj SS. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. International Journal of Infectious Diseases 2007;11(5):450-453.
129. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrobial Agents and Chemotherapy 2001;45(9):2628-30.
130. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al.Bacteraemia in febrile neutropenic cancer patients. International Journal of Antimicrobial Agents 2007;30 Suppl 1:S51-9.
131. Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. American Journal of Medical Sciences 1984;287(1):16-23.
132. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. Journal of Internal Medicine 1998;244(5):379-86.
133. Leibovici L, Yahav D, Paul M. Excess mortality related to Cefepime: Comment on the FDA review process and conclusions. Lancet Infectious Diseases 2010;Accepted for publication:EPUB.
134. Li C, Nicolau DP, Lister PD, Quintiliani R, Nightingale CH. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. Journal of Antimicrobial Chemotherapy 2004;53(2):297-304.
135. Lichaa H, Rachoin JS, Cerceo E, Rajput V, Surkis W. Cefepime: An underrecognized cause of nonconvulsive status epilepticus. Journal of Hospital Medicine 2010;5(3):E18-E19.
136. Link H, B?hme A, Cornely OA, H?ffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW, Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Annals of Hematology 2003;82 Suppl 2:S105-17.
137. Martin Herrera C, Navarro M. [Cefepime-induced encephalopathy in patients with renal failure]. Nefrologia 2009;29(2):181.
138. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
139. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al.Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clinical infectious Diseases 2004;39(1):31-7.
140. Paul M, Soares-Weiser K, Leibovici. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326(7399):1111.
141. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2004, Issue Issue 3.
142. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobical Chemotherapy 2005;55(4):436-444.
143. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: CD003914]
144. Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, et al.The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Israeli Medical Association Journal 2007;9(6):424-29.
145. Pechere JC, Vladoianu IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. Journal of Antimicrobial Chemotherapy 1992;29(5):563-73.
146. Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, et al.Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagnostic Microbiology and Infectious Diseases 1997;28(4):211-9.
147. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Journal of the Americal Medical Association 2006;295(10):1152-1160.
148. Raad I, Hachem R, Hanna H, Bahna P, Chatzinikolaou I, Fang X, et al.Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters. European Journal of Clinical Microbiology and Infectious Diseases 2007;26(8):549-56.
149. Rolston KV, Bodey GP. Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobical Chemotherapy 2006;58(2):478.
150. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. The Journal of Antimicrobial cChemotherapy 2006;58(5):987-93. [PUBMED: 16943209]
151. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. Journal of Infectious Diseases 1991;164(5):907-16.
152. Sanders CC. Cefepime: the next generation?. Clinical Infectious Diseases 1993;17(3):369-79.
153. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clinical Infectious Diseases 1996;23(3):454-61.
154. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama 1995;273(5):408-12.
155. Schwaber MJ, Graham CS, Sands BE, Gold HS, Carmeli Y. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrobial Agents and Chemotherapy 2003;47(6):1882-6.
156. Shaheen T, Volles D, Calland F, Sifri CD, Mytinger J, Hagspiel K, et al.Cefepime-associated status epilepticus in an ICU patient with renal failure. Journal of Chemotherapy 2009;21(4):452-54.
157. Storring RA, Jameson B, McElwain TJ, Wiltshaw E. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet 1977;2(8043):837-40.
158. Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. International Journal of Antimicrobial Agents 2005;Suppl 2:S123-7.
159. Thabet F, Al Maghrabi M, Al Barraq A, Tabarki B. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocritical care 2009;10(3):347-51.
160. Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, et al.Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagnostic Microbiology and Infectious Diseases 2009;64(3):320-6.
161. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Goncalves VM. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. European Journal of Clinical Microbiology & Infectious Diseases 2003;22(3):137-43.
162. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Diseases 2007;7(5):338-48.
163. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemothereapy 2006;57(2)(2):176-189.